시장보고서
상품코드
410981

메켈 세포암 : 파이프라인 리뷰

Merkel Cell Carcinoma (Oncology) - Drugs in Development, 2021

발행일: | 리서치사: Global Markets Direct | 페이지 정보: 영문 1010 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

메켈 세포암은 드물면서도 침습성이 강한 피부암으로, 재발과 전신 전이 위험이 높은 암입니다. 위험인자로는 연령, 성별, 희미한 피부색, 자외선 피폭 및 면역 억제 등이 있습니다. 보통 햇볕을 쬔 부위(얼굴, 손, 팔, 다리)에서 발병합니다. 치료법으로는 화학요법, 방사선치료, 수술 등이 있습니다.

메켈 세포암(Merkel Cell Carcinoma) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

서론

  • 조사 범위

메켈 세포암 개요

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/연구기관에서 연구중인 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발 참여 기업

  • Amgen Inc
  • Apcure SAS
  • BeiGene Ltd
  • Immune Design Corp
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • NantKwest Inc
  • Novartis AG
  • OncoSec Medical Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co., Ltd.

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

  • aNK Program
  • APC-001
  • avelumab
  • BGBA-317
  • DNA IL-12
  • EBC-46
  • G-100
  • nivolumab
  • pasireotide
  • pazopanib hydrochloride
  • pembrolizumab
  • Poly-ICLC
  • sapanisertib
  • talimogene laherparepvec
  • Vaccine to Target WT1 for Oncology

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.01.31

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2021, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure, and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 44, 18 and 8 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Merkel Cell Carcinoma - Overview
  • Merkel Cell Carcinoma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Merkel Cell Carcinoma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Merkel Cell Carcinoma - Companies Involved in Therapeutics Development
  • Merkel Cell Carcinoma - Drug Profiles
  • Merkel Cell Carcinoma - Dormant Projects
  • Merkel Cell Carcinoma - Discontinued Products
  • Merkel Cell Carcinoma - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제